Axcella Health Inc

NASDAQ:AXLA   3:59:50 PM EDT
2.64
+0.31 (+13.30%)
Regulatory, Earnings Announcements

Axcella Announces Results From Phase 2a Placebo Controlled Clinical Trial For Long Covid Subjects

Published: 08/02/2022 10:58 GMT
Axcella Health Inc (AXLA) - Axcella Announces Results From Phase 2a Placebo Controlled Clinical Trial for Long Covid Subjects.
Axcella - Subjects Receiving Axa1125 Experienced Clinically & Statistically Significant Improvement in Mental and Physical Fatigue Scores Versus.
Placebo.
Axcella - No Significant Difference on Primary Outcome Measure of PcrΤ Following Moderate Exercise Between Subjects Receiving Axa1125 and Placebo.
Axcella - Axa1125 Was Safe and Well Tolerated With No Significant Adverse Events Reported by Study Subjects.
Axcella - There Was a Notable Trend Toward Significant Improvement in Serum Lactate Levels After a 6mwt in Axa1125 Subjects (p=0.0730).
Axcella - Regulatory Meetings Are Planned to Discuss a Path to Registration Trial for Axa1125.
Further Company Coverage: Axlao ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.38

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.38

More details on our Analysts Page.